IGX.V - IntelGenx Technologies Corp.

TSXV - TSXV Delayed Price. Currency in CAD
0.2200
0.0000 (0.00%)
At close: 3:35PM EDT
Stock chart is not supported by your current browser
Previous Close0.2200
Open0.2200
Bid0.2200 x 0
Ask0.2350 x 0
Day's Range0.2200 - 0.2200
52 Week Range0.1600 - 0.9300
Volume1,910
Avg. Volume241,993
Market Cap24.729M
Beta (5Y Monthly)2.06
PE Ratio (TTM)N/A
EPS (TTM)-0.1140
Earnings DateAug. 07, 2018 - Aug. 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • GlobeNewswire

    IntelGenx Announces Adjusted VersaFilm® Business Strategy, Next Steps for RIZAPORT® VersaFilm® Program

    IntelGenx Technologies Corp. (TSX V:IGX)(IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced various initiatives aimed at helping the Company address, and satisfactorily respond to, the Complete Response Letter (“CRL”) that it recently received from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted 505(b)(2) New Drug Application for RIZAPORT® VersaFilm®, as well as maintain IntelGenx’s financial stability in light of the current market environment and the challenges posed by the global COVID-19 pandemic. While IntelGenx’s business development strategy will continue to focus on partnering its current product pipeline, which includes 10 pharmaceutical oral film product candidates, and pursuing potential oral thin film manufacturing opportunities, in light of recent unforeseeable developments, the Company will also accelerate its focus to pursue short-term revenue generating opportunities by expanding its pipeline to include additional products for which there is not an FDA or Health Canada (“HC”) approval requirement.

  • CNW Group

    IIROC Trading Resumption - IGX

    VANCOUVER , March 27, 2020 /CNW/ - Trading resumes in: Company: IntelGenx Technologies Corp. TSX-Venture Symbol: IGX (all issues) Resumption (ET): 12:15 PM IIROC can make a decision to impose a temporary ...

  • GlobeNewswire

    IntelGenx Receives Complete Response Letter from FDA for RIZAPORT® NDA

    IntelGenx Technologies Corp. (TSX V:IGX)(IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its resubmitted 505(b)(2) New Drug Application (“NDA”) for RIZAPORT® VersaFilm® for the treatment of acute migraines. The CRL states that the FDA cannot approve the application in its present form. “Obviously, we are surprised and disappointed,” said Dr. Horst G. Zerbe, CEO of IntelGenx.

  • CNW Group

    IIROC Trading Halt - IGX

    IIROC Trading Halt - IGX

  • GlobeNewswire

    IntelGenx Reports Fourth Quarter and Full-Year 2019 Financial Results

    IntelGenx Technologies Corp. (TSX V:IGX)(IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter and twelve-month periods ended December 31, 2019. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.

  • GlobeNewswire

    INTELGENX TO REPORT FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS ON MARCH 26; CONFERENCE CALL TO FOLLOW ON MARCH 27

    SAINT LAURENT, Quebec, March 23, 2020 -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its.

  • GlobeNewswire

    IntelGenx Completes C$8.2 Million Equity Offering

    IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has closed its offering (the “Offering”) of 16,317,000 units (the “Units”) at a price of C$0.50 per Unit (the “Offering Price”) for gross proceeds of C$8,158,500. Each Unit consists of one share of common stock (the “Offered Shares”) and one warrant (a “Warrant”) entitling the holder to purchase one share of common stock of the Company at an exercise price of C$0.75 per share (a “Warrant Share”).

  • GlobeNewswire

    IntelGenx Announces Pricing of Equity Offering

    IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) announced today the pricing of an agency offering (the “Offering”) of up to 20,000,000 units, subject to a minimum offering of 10,000,000 units (the “Units”), for gross proceeds of between $5,000,000 and $10,000,000, assuming no exercise of the over-allotment option granted to the Agent (as defined below), at a price of $0.50 per Unit. Each Unit will consist of one share (each, an “Offered Share”) of common stock of the Company (“Common Stock”) and one warrant (each, a “Warrant”) to purchase one share of Common Stock at an exercise price of $0.75 per share (a “Warrant Share”). The Offering is being conducted on a commercially reasonable best efforts basis by Echelon Wealth Partners Inc. (the “Agent”) in the provinces of British Columbia, Alberta, Manitoba and Ontario.

  • GlobeNewswire

    IntelGenx Receives Health Canada Authorization to Proceed with New Amendment for Montelukast VersaFilm® Phase 2a Trial

    - Ongoing BUENA Trial to Continue at Increased Daily Dose - SAINT LAURENT, Quebec, Jan. 15, 2020 -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in.

  • GlobeNewswire

    IntelGenx Provides Commercial Update on its Two Lead VersaFilm® Product Candidates, Cannabis-Infused Oral Film and RIZAPORT®

    “Because we believe this is an exciting product that will meet, if not exceed, consumer expectations, we think that we're well positioned to become a significant player in this expanding market as new product formats come online,” commented Dr. Horst G. Zerbe, CEO of IntelGenx.

  • GlobeNewswire

    IntelGenx Enters Animal Health Market by Signing Feasibility Agreement for VetaFilm™ Platform

    SAINT LAURENT, Quebec, Jan. 09, 2020 -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”) a leader in pharmaceutical films, today announced that it has entered into a.

  • GlobeNewswire

    IntelGenx Files Preliminary Short Form Prospectus in Connection With a Proposed Offering of Units

    IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has filed a preliminary short form prospectus (the “Prospectus”) with respect to an offering (the “Offering”) of units (“Units”) for a minimum of Cdn$4,000,000 and a maximum of Cdn$10,000,000 aggregate gross proceeds. Each Unit will consist of one share (an “Offered Share”) of the common stock of the Company (“Common Stock”) and one half of one common stock purchase warrant (each whole common stock purchase warrant, a “Warrant”).

  • GlobeNewswire

    IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures

    IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) announces that it intends to issue 415,178 common shares of the Corporation (the “Common Shares”) at a deemed price of CAD $0.73 per Common Share in payment of an aggregate of $303,080 in interest owing on the Corporation’s 8.00% convertible unsecured subordinated debentures due June 30, 2020 (the “Debentures”). Under the terms of the trust indenture governing the Debentures (the “Indenture”), the Corporation has the option to pay the semi-annual interest on the Debentures in either cash or Common Shares, subject to customary conditions set forth in the Indenture.

  • GlobeNewswire

    IntelGenx to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

    SAINT LAURENT, Quebec, Dec. 03, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced.

  • GlobeNewswire

    IntelGenx Reports Third Quarter 2019 Financial Results

    SAINT LAURENT, Quebec, Nov. 07, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today reported.

  • GlobeNewswire

    IntelGenx to Report Third Quarter 2019 Financial Results on November 7, 2019 – Conference Call to Follow

    SAINT LAURENT, Quebec, Nov. 01, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced.

  • GlobeNewswire

    IntelGenx Initiates Scale-Up Work for Cannabis-Infused Oral Film Product

    SAINT LAURENT, Quebec, Oct. 31, 2019 -- IntelGenx Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has.

  • GlobeNewswire

    IntelGenx Announces FDA’s Acceptance of Resubmitted RIZAPORT® New Drug Application

    SAINT LAURENT, Quebec, Oct. 22, 2019 -- IntelGenx Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that its.

  • GlobeNewswire

    IntelGenx Receives Positive DSMB Recommendation for Montelukast VersaFilm® Phase 2a Trial

    IntelGenx Corp. (IGX.V)(IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that an independent Data Safety Monitoring Board (“DSMB”) completed its first interim analysis of the ongoing Montelukast VersaFilm® Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”). The DSMB reviewed compiled safety data from 25 subjects enrolled in the BUENA trial, 13 of which have completed 26 weeks of daily treatment. The DSMB did not raise any concerns regarding safety and recommended that the trial continue.

  • GlobeNewswire

    IntelGenx Announces Resubmission of RIZAPORT® New Drug Application

    IntelGenx Corp. (IGX.V)(IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has resubmitted its 505(b)(2) New Drug Application (“NDA”) for RIZAPORT® VersaFilm® for the treatment of acute migraines to the U.S. Food and Drug Administration (“FDA”). “Over the past several months, we have been working diligently to address the FDA’s questions and resubmit this NDA in a timely manner,” commented Dr. Horst G. Zerbe, CEO of IntelGenx. On April 2, 2019, the Company announced that it had received a Complete Response Letter (“CRL”) from the FDA regarding the NDA for RIZAPORT® VersaFilm® accepted by the Agency on November 20, 2018.